Replies to post #985 on Alimera Sciences Inc (ALIM)

[mick]

'ATLANTA, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has filed a certificate of amendment to its restated certificate with the Secretary of State of the State of Delaware that will effect the previously announced one-for-15 reverse stock split of its common stock. The certificate of amendment provides that the reverse stock split will become effective at 5:01 PM Eastern Time today, after the close of trading on The Nasdaq Global Market. On November 15, 2019, Alimera’s common stock will begin trading on a post-reverse stock split basis on The Nasdaq Global Market under the existing symbol “ALIM.”

About Alimera Sciences, Inc.

Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the management of retinal diseases. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.

Forward-Looking Statements

This press release contains a “forward-looking statement” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Alimera’s expectation that its common stock will trade The Nasdaq Global Market on a post-reverse stock split basis on November 15, 2019. The forward-looking statement is based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change this expectation, and could cause actual results to differ materially from those projected in the forward-looking statement. Meaningful factors that could cause actual results to differ include, but are not limited to, unforeseen technical issues that could result in Alimera’s common stock not trading on The Nasdaq Global Stock Market on a post-reverse stock split basis on November 15, 2019 as expected.

For press inquiries:
Jules Abraham
for Alimera Sciences
917-885-7378
[e-mail]

For investor inquiries:
Scott Gordon
for Alimera Sciences
[e-mail]

[mick]

wow/\ $ALIIM/


wow/\ $ALIIM/ [-chart]ih.advfn.com/p.php?pid=staticchart&s=ALIM&p=0&t=17&width=336&height=112&vol=1&min_pre=180[/chart]

[mick]

People Wanting This Treatment "THE RIGHT TO TRY"/\Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019
GlobeNewswire GlobeNewswire•December 4, 2019

ATLANTA, Dec. 04, 2019 (GLOBE NEWSWIRE)
-- Alimera Sciences, Inc. (ALIM) (“Alimera” or “Company”), a leader
in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases,

today announces that Rick Eiswirth, President and Chief Executive Officer of Alimera, will be a featured presenter at the LD Micro Main Event on
Tuesday, December 10, 2019 at 12:40 PM Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Mr. Eiswirth will provide an overview of the company’s business
model and growth strategy and will be available for one-on-one meetings.

In addition, his presentation will be webcast. To access the webcast, please visit

http://wsw.com/ldmicro17/alim at the time of the presentation.

The webcast will also be archived for 90 days and may be subsequently accessed on the Company’s website.

For those interested in attending or for registered attendees who wish to request meetings,
please contact David Scher at [e-mail] or visit
http://www.ldmicro.com for more information.

About Alimera Sciences, Inc.

Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the management of retinal diseases.

Alimera is presently focused on diseases affecting the back of the eye, or retina,
because these diseases are not well treated with current therapies
and will affect millions of people in our aging populations.

For more information, please visit http://www.alimerasciences.com.

About ILUVIEN®

The Company’s primary product is ILUVIEN
(fluocinolone acetonide intravitreal implant)
0.19 mg sustained release intravitreal implant,
injected into the back of the eye.

With its CONTINUOUS MICRODOSING™ technology, ILUVIEN is designed to release sub-microgram levels of fluocinolone acetonide,

a corticosteroid, for 36 months,
to reduce the recurrence of disease,
enabling patients to maintain vision longer with fewer injections.

ILUVIEN is approved in the
U.S.,
Canada,
Kuwait,
Lebanon and
the U.A.E
to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not
have a clinically significant rise in intraocular pressure.

In 17 European countries, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered
insufficiently responsive to available therapies.

In March 2019, ILUVIEN received approval in the 17 countries under
the Mutual Recognition Procedure for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

The
17 European countries include the
U.K.,
Germany,
France,
Italy,
Spain,
Portugal,
Ireland,
Austria,
Belgium,
Denmark,
Norway,
Finland,
Sweden,
Poland,
Czech Republic,
the Netherlands, and
Luxembourg.

The regulatory process is now in the national phase in which the European member states have finalized or are expected to finalize
the label for the new indication to meet each country’s local requirements.

Timeline to this goal varies by each country,
and the non-infectious posterior uveitis indication for ILUVIEN
was launched in
Germany and
the U.K. in 3Q 2019.

ILUVIEN is not approved for treatment of uveitis in the United States.

For press inquiries:

For investor inquiries:
Jules Abraham Scott Gordon
for Alimera Sciences for Alimera Sciences
917-885-7378 [e-mail]
[e-mail]